Repurposing niclosamide ethanolamine for alveolar echinococcosis reveals a disconnect between in vitro efficacy and in vivo outcome in the intraperitoneal infection model
PLOS Neglected Tropical Diseases · 2026
DOI: 10.1371/journal.pntd.0014016 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, 2026. Verfasst von Matías Preza und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Parasitology, Vetsuisse Faculty, University of Bern, Bern, Switzerland. Hauptthemen laut MEDLINE: Niclosamide, Echinococcus multilocularis, Anthelmintics, Drug Repositioning. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Uniscientia Stiftung, Gottfried und Julia Bangerter-Rhyner-Stiftung, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.
Abstract (Originalsprache)
Background Echinococcosis is a zoonotic disease caused by cestodes of the genus Echinococcus . Alveolar echinococcosis (AE), caused by E. multilocularis , primarily affects the liver and shows infiltrative, tumor-like growth of the metacestode stage. If untreated, AE is lethal. AE remains a neglected disease with current treatments based on albendazole or mebendazole that are parasitostatic, and not curative, underscoring the need for more effective therapies. Niclosamide is a chlorinated salicylanilide derivative with proven activities against intestinal helminths but is inactive against tissue-dwelling helminths due to poor absorption and limited bioavailability. In this study, we repurposed niclosamide ethanolamine (NEN), a formulation with improved systemic exposure, for the treatment of E. multilocularis infection in vitro and in vivo . Methodology/principal findings We assessed the in vitro efficacy of niclosamide and NEN against E. multilocularis metacestode vesicles (IC 50 < 0.2 µM) and primary parasite cells (IC 50 < 0.3 µM), with active concentrations largely corresponding to NEN levels reachable in the liver. Metabolic analysis suggested that NEN acts as a mitochondrial uncoupler. Electron microscopy showed that NEN-treatments induced profound structural damage in the metacestode vesicle tissue, but mitochondrial ultrastructure was not notably affected. In mice intraperitoneally infected with E. multilocularis , NEN was orally administered during 9 weeks either alone, or in combination with albendazole. Pharmacokinetic analyses showed that NEN reached blood level concentrations above 1 µM. However, the parasite burden in NEN-treated mice was not significantly reduced under the conditions used in this study. Conclusions/significance Although niclosamide and NEN demonstrated potent activity against E. multilocularis in vitro , this efficacy did not translate in the mouse model. The lack of in vivo activity could be attributed to several factors such as infection model, limited drug uptake by the parasite in the animal, or the rapid metabolization of the compound. Future studies should explore novel niclosamide derivatives and formulations to enhance efficacy against AE in vivo .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Parasitology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
- Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland.
- CNRS, ISCR (Institut des Sciences Chimiques de Rennes)-UMR 6226, University of Rennes, Rennes, France.
- Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, University of Rennes, Inserm, EHESP, Rennes, France.
- Multidisciplinary Center for Infectious Diseases, University of Bern, Bern, Switzerland.
ORCID-Profile: Britta Lundström-Stadelmann
Förderung
- Uniscientia Stiftung
- Gottfried und Julia Bangerter-Rhyner-Stiftung
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Zitieren
APA
Preza, M., Dietrich, N., Zumstein, P., Steinmann, J., Hiller, L., Zumkehr, T., Kämpfer, T., Chollet-Krugler, M., Vetter, L., Hemphill, A., Dion, S., & Lundström-Stadelmann, B. (2026). Repurposing niclosamide ethanolamine for alveolar echinococcosis reveals a disconnect between in vitro efficacy and in vivo outcome in the intraperitoneal infection model. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0014016
Vancouver
Preza M, Dietrich N, Zumstein P, Steinmann J, Hiller L, Zumkehr T, et al. Repurposing niclosamide ethanolamine for alveolar echinococcosis reveals a disconnect between in vitro efficacy and in vivo outcome in the intraperitoneal infection model. PLOS Neglected Tropical Diseases. 2026. doi:10.1371/journal.pntd.0014016
BibTeX
@article{Preza2026,
author = {Preza, Matías and Dietrich, Nicole and Zumstein, Pascal and Steinmann, Judith and Hiller, Lea and Zumkehr, Trix and Kämpfer, Tobias and Chollet-Krugler, Marylène and Vetter, Laura and Hemphill, Andrew and Dion, Sarah and Lundström-Stadelmann, Britta},
title = {Repurposing niclosamide ethanolamine for alveolar echinococcosis reveals a disconnect between in vitro efficacy and in vivo outcome in the intraperitoneal infection model},
journal = {PLOS Neglected Tropical Diseases},
year = {2026},
doi = {10.1371/journal.pntd.0014016}
}
EUVIMED